Clovis Oncology
Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder, CO 80301
Phone: (303) 625-5000Website: https://clovisoncology.com/Careers: clovisoncology.com/careers
Latest news
- Rubraca (rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
15 May 2020 - Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
6 April 2018 - FDA Grants Accelerated Approval to Rubraca (rucaparib) for Advanced Ovarian Cancer
19 December 2016 - FDA Accepts Clovis Oncology’s NDA for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
23 August 2016
Drugs Associated with Clovis Oncology, Inc.
Clovis Oncology, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
